HC Wainwright set a $30.00 price objective on XOMA (NASDAQ:XOMA) in a research report report published on Friday morning, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on the stock. Wedbush restated a buy rating and issued a $25.00 target price on shares of XOMA in a report on Wednesday, August 7th. ValuEngine cut shares of XOMA from a buy rating to a hold rating in a research note on Tuesday, August 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. XOMA presently has a consensus rating of Hold and an average price target of $27.50.
Shares of XOMA stock traded up $0.76 during trading hours on Friday, hitting $19.52. The company had a trading volume of 27,738 shares, compared to its average volume of 60,764. The company’s 50-day moving average is $18.12 and its two-hundred day moving average is $16.16. XOMA has a twelve month low of $11.02 and a twelve month high of $22.00. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.90 and a quick ratio of 3.90. The company has a market cap of $173.07 million, a P/E ratio of -12.28 and a beta of 1.26.
XOMA (NASDAQ:XOMA) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. XOMA had a negative net margin of 72.20% and a negative return on equity of 51.91%. The business had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $0.63 million. Sell-side analysts expect that XOMA will post -1.15 EPS for the current year.
In related news, CFO Thomas M. Burns sold 3,829 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $21.96, for a total transaction of $84,084.84. Following the completion of the sale, the chief financial officer now owns 10,384 shares in the company, valued at approximately $228,032.64. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James R. Neal sold 3,830 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $21.96, for a total transaction of $84,106.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,111 shares of company stock valued at $278,486. 9.89% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the stock. RBF Capital LLC purchased a new position in XOMA during the 2nd quarter worth $1,479,000. Stonepine Capital Management LLC raised its position in XOMA by 18.9% during the 2nd quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock worth $4,019,000 after buying an additional 43,019 shares during the last quarter. Paloma Partners Management Co purchased a new position in XOMA during the 2nd quarter worth $510,000. Marshall Wace LLP purchased a new position in XOMA during the 2nd quarter worth $434,000. Finally, Morgan Stanley raised its position in XOMA by 2,151.6% during the 2nd quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares during the last quarter. Hedge funds and other institutional investors own 44.47% of the company’s stock.
XOMA Company Profile
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.
See Also: Bond
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.